Your browser doesn't support javascript.
loading
Novel poly(lactic-co-glycolic acid) nanoliposome-encapsulated diclofenac sodium and celecoxib enable long-lasting synergistic treatment of osteoarthritis.
Chu, Bo; Chen, Dagui; Ma, Senlin; Yang, Yong; Shang, Fusheng; Lv, Wei; Li, Yinghua.
Afiliación
  • Chu B; Orthopaedics, Wuxi Xishan People's Hospital, Wuxi, China.
  • Chen D; Institute of Translational Medicine, Shanghai University, Shanghai, China.
  • Ma S; Department of Emergency Medicine, Huashan Hospital, Fudan University, Shanghai, China.
  • Yang Y; Orthopaedics, Wuxi Xishan People's Hospital, Wuxi, China.
  • Shang F; Institute of Translational Medicine, Shanghai University, Shanghai, China.
  • Lv W; Orthopaedics, Wuxi Xishan People's Hospital, Wuxi, China.
  • Li Y; Institute of Translational Medicine, Shanghai University, Shanghai, China.
J Biomater Appl ; 39(3): 221-234, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38820587
ABSTRACT

BACKGROUND:

Diclofenac sodium (DS) and celecoxib (CEL) are primary anti-inflammatory agents used in the treatment of osteoarthritis (OA). Formulating these drugs into extended-release versions can effectively address the issue of multiple daily doses. In this study, we designed and synthesized a novel poly(lactic-co-glycolic acid) (PLGA) nanoliposome as a dual-drug delivery sustained-release formulation (PPLs-DS-CEL) to achieve long-lasting synergistic treatment of OA with both DS and CEL.

METHODS:

PPLs-DS-CEL was synthesized by the reverse evaporation method and evaluated for its physicochemical properties, encapsulation efficiency, drug release kinetics and biological properties. A rat OA model was established to assess the therapeutic efficacy and biosafety of PPLs-DS-CEL.

RESULTS:

The particle size of PPLs-DS-CEL was 218.36 ± 6.27 nm, with a potential of 32.56 ± 3.28 mv, indicating a homogeneous vesicle size. The encapsulation of DS and CEL by PPLs-DS-CEL was 95.18 ± 4.43% and 93.63 ± 5.11%, with drug loading of 9.56 ± 0.32% and 9.68 ± 0.34%, respectively. PPLs-DS-CEL exhibited low cytotoxicity and hemolysis, and was able to achieve long-lasting synergistic analgesic and anti-inflammatory therapeutic effects in OA through slow release of DS and CEL, demonstrating good biosafety properties.

CONCLUSION:

This study developed a novel sustained-release nanoliposomes formulation capable of co-loading two drugs for the long-acting synergistic treatment of OA. It offers a new and effective therapeutic strategy for OA treatment in the clinic settings and presents a promising approach for drug delivery systems.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoartritis / Antiinflamatorios no Esteroideos / Diclofenaco / Preparaciones de Acción Retardada / Celecoxib / Copolímero de Ácido Poliláctico-Ácido Poliglicólico / Liposomas Límite: Animals / Humans / Male Idioma: En Revista: J Biomater Appl Asunto de la revista: ENGENHARIA BIOMEDICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoartritis / Antiinflamatorios no Esteroideos / Diclofenaco / Preparaciones de Acción Retardada / Celecoxib / Copolímero de Ácido Poliláctico-Ácido Poliglicólico / Liposomas Límite: Animals / Humans / Male Idioma: En Revista: J Biomater Appl Asunto de la revista: ENGENHARIA BIOMEDICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido